Oesophageal cancer test ‘should be made more available in UK’

A test that can detect oesophageal cancer at an earlier stage than current methods should be made more widely available to prevent deaths, charities have said.

The capsule sponge test, previously known as Cytosponge, involves a patient swallowing a dissolvable pill on a string. The pill then releases a sponge which collects cells from the oesophagus as it is retrieved.

The test can detect abnormalities that form as part of a condition known as Barrett’s oesophagus, which makes a person more likely to develop oesophageal cancer.

In the UK 9,300 people are diagnosed with oesophageal cancer a year, according to Cancer Research. The disease is difficult to detect because the symptoms for the cancer are not easily recognisable – and can be mistaken for indigestion – until a it is at an advanced stage.

The capsule sponge test can detect the cancer at an earlier stage than the current methods, such as an endoscopy, used to diagnose oesophageal cancer. However, it is only currently available to higher-risk patients as an alternative to endoscopy as part of NHS pilot schemes.

Cancer Research UK is working with the National Institute for Health and Care Research (NIHR) on a trial that will recruit 120,000 people to see if the capsule sponge test can reduce deaths from oesophageal cancer. If successful, the test could be rolled out more widely.

Mimi McCord, the founder of Heartburn Cancer UK, who lost her husband, Mike, to oesophageal cancer in 2002, said: “Cancer of the oesophagus is a killer that can hide in plain sight. People don’t always realise it, but not all heartburn is harmless. While they keep on treating the symptoms, the underlying cause might be killing them.”

Read full story

Source: The Guardian, 5 February 2024